Deep Tech Catalyst · Jun 2026
Profiles Signatur Biosciences’ DTC Bio-supported work broadening PCRchitectur from a single lead product to a wider precision-diagnostics platform.
Simple tests for complex diseases.
Company research
Public company, workplace, funding, and market signals
Overview
Signatur Biosciences is a London-headquartered biotech spinout founded in 2022 that is building PCRchitectur, a platform that lets standard qPCR machines run decentralized molecular diagnostics, starting with breast cancer prognosis.
Primary product
OncoSignatur Breast (OSB), a qPCR-based breast cancer prognostic test kit powered by PCRchitectur
Founded
2022
Headquarters
London, United Kingdom
Team size
11-50
Work style
Remote
Industry
Biotechnology Research
Sub-industry
Molecular diagnostics
Offices
London, United Kingdom
Liège, Belgium
New York, New York, United States
Business model
B2B diagnostic kits
platform partnerships
assay development for clinical labs
Funding
Stage
Seed
Total raised
$9.9M
Latest round
Seed · May 2025
Latest amount
$7M
People & investors
Leadership
Co-founder and CEO
Bertrand Duquesne
Chief Operating Officer
Adrian Moody
Chief Development Officer
Vincent Colin
Chief Financial Officer
Leigh Pugh
Head of Commercial Development
Nahimi Amare Bekele
Head of RA/QA
Francesca Smith
Lead Scientist
Edwicka Gregorowicz
Head of Lab Operations
Olivia Lefevre
Product Lead
Scientific Advisory Board Chair
Scientific Advisor
Work & culture
Mission-driven and fast-moving, with an emphasis on employee empowerment, simplicity, diversity, equity and inclusion, and working in a primarily remote, flexible setup.
Work style
Remote
Compensation
Open roles advertise a competitive base salary based on experience; no public salary bands or full compensation package were disclosed.
Benefits
4 weeks paid time off
12 compensatory days
private medical insurance
remote/flexible work
Product & market
Pricing
Not publicly disclosed; appears to be a B2B kit and platform-partnership model for clinical laboratories and diagnostic partners.
Differentiators
- —Runs on standard qPCR machines already present in clinical labs
- —Condenses complex RNA/gene-expression signatures into a single assay
- —Designed for decentralized local testing instead of centralized reference labs
- —Faster turnaround in days or hours rather than weeks
- —Lower material cost than conventional genomic testing
- —Works with off-the-shelf reagents and existing workflows
Technology
PCRchitectur
standard qPCR instruments
off-the-shelf reagents
single-assay gene-expression profiling
molecular machine learning
competitive PCR biology
ISO 13485 quality systems
high-throughput liquid handling
Customers
hospitals
clinical laboratories
biomedical laboratories
diagnostic partners
Competitors
Exact Sciences
GRAIL
Foundation Medicine
Guardant Health
Scale & contact
Latest news
N24 · May 2025
Another independent write-up of the seed round, total funding, and the company’s plan to decentralize breast-cancer testing for hospital labs.
TechFundingNews · May 2025
Coverage of the seed round, the move to a Liège lab, and the product strategy to run breast-cancer prognostic testing on standard qPCR machines in local labs.
Signatur Biosciences · Apr 2025
Official company announcement of the $7M Seed round, bringing total funding to $9.9M, naming The Discovery Lab of IBA and Noshaq, and describing the first product OncoSignatur Breast and the Liège lab expansion.
Jobs and careers at Signatur Biosciences
0 jobs at Signatur Biosciences
No open positions
Check back later for new openings